Get the Stockscreener App
2.17
0.93%
0.02
After Hours:
2.17
Jyong Biotech Ltd stock is traded at $2.17, with a volume of 57,926.
It is up +0.93% in the last 24 hours and down -0.91% over the past month.
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
See More
Previous Close:
$2.15
Open:
$2.1
24h Volume:
57,926
Relative Volume:
0.36
Market Cap:
$161.09M
Revenue:
-
Net Income/Loss:
$-2.95M
P/E Ratio:
-53.98
EPS:
-0.0402
Net Cash Flow:
-
1W Performance:
-0.46%
1M Performance:
-0.91%
6M Performance:
-92.77%
1Y Performance:
+0.00%
1-Day Range:
$2.09
$2.19
1-Week Range:
$2.0065
$2.19
52-Week Range:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.17 | 159.60M | 0 | -2.95M | 0 | -0.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jyong Biotech Ltd Stock (MENS) Latest News
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZonePCR Divergence - Newser
Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser
Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - marketscreener.com
Jyong Biotech (NASDAQ: MENS) flags Botreso FDA hurdles and $19.4M judgment - Stock Titan
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025 - Quiver Quantitative
Inside Jyong Biotech's 2025 SEC annual report filing for investors - Stock Titan
What Jyong Biotech (MENS) management focus reveals about priorities (Risk Aversion) 2026-05-11Crowd Sentiment Stocks - Newser
Jyong Biotech Delays Annual 20-F (Yearly Report) - The Globe and Mail
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio - The Manila Times
Jyong Biotech Updates Market Access Strategy for Innovative - GlobeNewswire
Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Decreases By 43.2% - MarketBeat
CEO-linked entities report 33.34% Jyong Biotech (MENS) stake via trust - Stock Titan
Jyong Biotech (MENS) Management Strategy | Q1 2025: Earnings ReportPre Earnings - Cổng thông tin điện tử tỉnh Lào Cai
Who Backs Jyong Biotech (MENS) Stock (Risk Aversion) 2026-04-20Investment Picks - Cổng thông tin điện tử tỉnh Lào Cai
Ming Tsan Hsu Net Worth (2026) - GuruFocus
Pang Chieh Chi Net Worth (2026) - GuruFocus
Hung Shu Fan Net Worth (2026) - GuruFocus
Feng Lin Hsu Net Worth (2026) - GuruFocus
Fu Feng Kuo Net Worth (2026) - GuruFocus
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Significant Decrease in Short Interest - MarketBeat
Jyong Biotech Ltd. Live Share Prices and Trades. MENS.US Live Streaming Share Prices. - London South East
Jyong Biotech (NASDAQ: MENS) CFO ZHANG WEI files initial Form 3 - Stock Titan
Wei (vivi) Zhang Net Worth (2026) - GuruFocus
MENS Options Volatility — NASDAQ:MENS - TradingView
MENS Options Chain — NASDAQ:MENS - TradingView
MENS News | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech (MENS) CEO Kuo reports 25,349,500-share indirect stake on Form 3 - Stock Titan
Is Jyong Biotech (MENS) Stock Rebounding | Price at $2.47, Up 0.82%Analyst Upgrade Stocks - Newser
MENS PE Ratio & Valuation, Is MENS Overvalued - Intellectia AI
Director of Jyong Biotech (MENS) files Form 3 showing 3,000 common shares - Stock Titan
Director Hsu Feng-Lin reports 3,000 Jyong Biotech (MENS) shares on Form 3 - Stock Titan
Director at Jyong Biotech (MENS) discloses holding 3,000 shares - Stock Titan
Jyong Biotech (MENS) director Fan Hung-Shu files initial Form 3 - Stock Titan
Jyong Biotech (MENS) director files Form 3 with no insider trades - Stock Titan
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March - Defense World
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 - The Manila Times
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 - Bitget
Jyong Biotech Ltd PE Ratio (TTM) & PE Ratio (TTM) ChartsMENS - GuruFocus
Chinese firm sues Taiwan’s Jyong Biotech Ltd. in Cayman to enforce ¥152M China judgment - OffshoreAlert
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest - MarketBeat
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
MENS Earnings History & Surprises | EPS & Revenue Results | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
MENS Should I Buy - Intellectia AI
Jyong Biotech Ltd Stock (MENS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):